Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Autor: C. Seynaeve, E. Donato Di Paola, Siow Ming Lee, Ian Judson, D. Tonelli, Jaap Verweij, R. Van Hoessel, Wlodzimierz Ruka, Robert E. Coleman, J. Buesa, M. van Glabbeke

Publikováno v: International Journal of Clinical Oncology, 18, 2081-2086
International Journal of Clinical Oncology, 18, 10, pp. 2081-2086
Journal of Clinical Oncology, 18, 2081-2086. American Society of Clinical Oncology

PURPOSE: To assess antitumor response and time to progression (TTP) with docetaxel compared with doxorubicin in first-line treatment of advanced and/or metastatic soft tissue sarcoma. PATIENTS AND METHODS: Patients with measurable soft tissue sarcoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b507edc8a9cb00a2cd9d526314162b60
https://doi.org/10.1200/jco.2000.18.10.2081